Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis

Keyphrases

• Experimental Autoimmune Encephalomyelitis 100%
• VLA-4 100%
• Disease Onset 50%
• Multiple Sclerosis 33%
• Central Nervous System 33%
• Clinical Disease 33%
• Encephalitogenic T Cells 33%
• Integrin 16%
• Autoimmune Disease 16%
• Immune System 16%
• Myelin 16%
• Remission 16%
• Epitope 16%
• Activated T Cells 16%
• Vascular Cell Adhesion molecule-1 (VCAM-1) 16%
• CD4+ T Cells 16%
• Inflammatory Cells 16%
• Tissue Damage 16%
• Disease Relapse 16%
• Acute Disease 16%
• Multiple Effects 16%
• Th1 Response 16%
• Cerebral Endothelial Cell 16%
• PLP1 16%

Immunology and Microbiology

• Experimental Autoimmune Encephalomyelitis 100%
• VLA-4 100%
• T Cell 50%
• Multiple Sclerosis 33%
• Peptides 33%
• Central Nervous System 33%
• Epitope 16%
• Integrin 16%
• T-Helper Cell 16%
• Autoimmune Disease 16%
• Inflammatory Cell 16%
• Immune System 16%
• VCAM-1 16%
• Myelin 16%

Neuroscience

• Experimental Autoimmune Encephalomyelitis 100%
• VLA-4 100%
• T Cell 66%
• Multiple Sclerosis 33%
• Central Nervous System 33%
• Myelin 16%
• Autoimmune Disease 16%
• Integrin 16%
• CD4 16%
• Epitope 16%
• VCAM-1 16%
• Proteolipid Protein 16%